Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Chordia Therapeutics Inc. ( (JP:190A) ) has issued an update.
Chordia Therapeutics Inc. announced it has received a grant for a non-clinical study of novel therapeutic agents for refractory tumors with RNA splicing mutations, in collaboration with Kyoto University. The grant, part of a project by the Japan Agency for Medical Research and Development, will be recorded as non-operating income and is not expected to impact the company’s current fiscal year business forecast.
More about Chordia Therapeutics Inc.
Chordia Therapeutics Inc. operates in the biotechnology industry, focusing on the development of innovative cancer therapies. Its lead product, rogocekib (CLK inhibitor CTX-712), is in Phase 1/2 clinical trials in the US, targeting cancer vulnerabilities. The company is also researching several preclinical assets, including a MALT1 inhibitor, a CDK12 inhibitor, and GCN2 inhibitors.
Average Trading Volume: 858,927
Technical Sentiment Signal: Strong Sell
Find detailed analytics on 190A stock on TipRanks’ Stock Analysis page.